Publications by authors named "Mark Mullin"

Claim this Profile
A
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Dordaviprone.
Shamia L Faison, Joelle Batonga, Thangam Arumugham, Angela Bartkus, Marion E Morrison, Mark J Mullin

J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults.
Shamia L Faison, Joelle Batonga, Thangam Arumugham, Angela Bartkus, Marion E Morrison, Mark J Mullin

Br J Clin Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Severe Renal Impairment on Dordaviprone (ONC201) Pharmacokinetics.
Shamia L Faison, Joelle Batonga, Thangam Arumugham, Angela Bartkus, Marion E Morrison, Mark J Mullin

Drugs R D· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult Participants.
Yohannes Teffera, Tim Tippin, Angela Bartkus, Francine A de Castro, Shamia L Faison, Mark J Mullin

Clin Pharmacol Drug Dev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects.
Shamia L Faison, Joelle Batonga, Thangam Arumugham, Angela Bartkus, Marion Morrison, Mark J Mullin

Clin Pharmacol Drug Dev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co-Administration of the Proton-Pump Inhibitor Rabeprazole.
Shamia L Faison, Joelle Batonga, Thangam Arumugham, Angela Bartkus, Marion Morrison, Mark J Mullin

J Clin Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood mononuclear cells isolation from mouse and rabbit blood to quantify active nucleotide and define brincidofovir dose for smallpox.
Robert Hart, Shane Karnik, Kathy Van Sickle, Mark Mullin, Odin Naderer

Bioanalysis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.
Jennifer C Goodell, Sara M Zimmerman, Cody J Peer, Varun Prabhu, Tyler Yin, Mark Mullin

J Pharm Biomed Anal· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction notice to: Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity.
James P. Warne, Farzad Alemi, Alison S. Reed, Jillian M. Varonin, Helen Chan, Mark E. Mullin

Cell Metab· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity.
James P Warne, Farzad Alemi, Alison S Reed, Jillian M Varonin, Helen Chan, Mark E Mullin

Cell Metab· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis